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Background: Telavancin is a lipoglycopeptide with multiple mechanisms of action that include mem-
brane-destabilizing effects towards bacterial cells. It shows bactericidal activity against forms of
Staphylococcus aureus (phagolysosomal infection) with different resistance phenotypes [methicillin-
resistant S. aureus, vancomycin-intermediate S. aureus or vancomycin-resistant S. aureus]. We
examine here the uptake, efﬂux and intracellular distribution of telavancin in eukaryotic cells as well as
its potential to induce lysosomal changes (in comparison with vancomycin and oritavancin).
Methods: J774 macrophages and rat embryo ﬁbroblasts were exposed for up to 24 and 72 h to telavan-
cin (5–90 mg/L). The following studies were performed: measurement of
14C-labelled telavancin cellu-
lar uptake and subcellular distribution (cell fractionation), determination of pericellular membrane
integrity (lactate dehydrogenase release), electron microscopy with morphometric analysis of changes
in lysosome size and determination of total phospholipid and cholesterol content.
Results: The uptake of telavancin proceeded linearly as a function of time and concentration in both
cell types (clearance rate of 10 mL/g of protein/h). Efﬂux (macrophages) was 5.7-fold slower.
Telavancin subcellular distribution was superimposable on that of a lysosomal marker (N-acetyl-b-
hexosaminidase). It did not cause an increase in the release of lactate dehydrogenase and did not
induce signiﬁcant increases in total phospholipid or cholesterol content. It caused only mild morpho-
logical lysosomal alterations (similar to vancomycin and much less than oritavancin by morphometric
analysis).
Conclusions: Telavancin is taken up by eukaryotic cells and localizes in lysosomes, causing mild mor-
phological alterations without evidence of lipid metabolism alterations. These data support our obser-
vations that telavancin is active against intracellular S. aureus.
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Introduction
Telavancin is a novel lipoglycopeptide derivative of vancomy-
cin
1 with marked bactericidal activity against vancomycin-
susceptible and vancomycin-resistant organisms
2 due to a
multifunctional mechanism of action that combines inhibition of
cell wall synthesis and disruption of bacterial cell membrane
permability.
3 It shows a high penetration in tissues,
4 including
human alveolar macrophages.
5 In a recent study, we showed that
telavancin exerts time- and concentration-dependent bactericidal
activity against intraphagocytic Staphylococcus aureus, disre-
garding their resistance phenotypes (methicillin-resistant
S. aureus, vancomycin-intermediate S. aureus or vancomycin-
resistant S. aureus).
6
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rationalize this observation by examining the uptake and subcellu-
lar disposition of telavancin in eukaryotic cells. Because previous
studies had disclosed marked lysosomal alterations in eukaryotic
cells exposed to another lipoglycopeptide, oritavancin,
7 we also
undertook to assess the impact of telavancin in this context, using
vancomycin as a comparator. The study was performed with both
phagocytic (J774 macrophages) and non-phagocytic (ﬁbroblasts)
cells because this allowed us, in the past, to obtain a comprehen-
sive picture of the behaviour of other antibiotics accumulating in
cells and causing speciﬁc lysosomal alterations.
8–11
Materials and methods
Cells, cell cultures and assessment of membrane integrity
J774 mouse macrophages and rat embryo ﬁbroblasts were cultivated,
as previously described,
7 in RPMI 1640 or in Dulbecco’s modiﬁed
Eagle’s medium, respectively, both supplemented with 10% fetal
calf serum (unless stated otherwise). The integrity of the pericellular
membrane upon exposure to the antibiotics was assessed by measur-
ing the release of lactate dehydrogenase in the culture medium, as
described previously.
6
Determination of cellular antibiotic concentration
Cells incubated with
14C-labelled telavancin were washed three
times in ice-cold 0.9% NaCl, collected by scraping in distilled water
and used for radioactivity determination (liquid scintillation count-
ing) and protein assay (a detailed description of the methodology
has been published previously
12). In pilot experiments,
cell-associated antibiotic was also measured by a microbiological
technique (with Micrococcus luteus ATCC 9341 as test organism
and antibiotic medium 11).
12 A correlation coefﬁcient (R
2) of 0.95
was found between the two methods for cells incubated 24 h at con-
centrations spanning from 10 to 100 mg/L (n ¼ 12).
Cell fractionation studies
Cells were collected by gentle scraping in 0.25 M sucrose/1 mM
EGTA/3 mM imidazole pH 7.4, homogenized and fractionated, as
described previously.
12 In brief, homogenates were separated into an
‘unbroken cells/nuclei’ fraction by a low-speed centrifugation. The
resulting cytoplasmic extract was separated into a ‘granules/mem-
branes’ fraction and a ﬁnal supernatant by high-speed centrifugation.
The granule/membrane fraction was then further analysed by isopyc-
nic centrifugation in a sucrose gradient. Protein and [
14C]telavancin
contents were determined in the fractions in parallel with the
activity of marker enzymes of the main organelles, namely, inosine
50-diphosphatase (E.C. 3.6.1.6.; plasma and endoplasmic reticulum
membranes), cytochrome c oxidase (E.C. 1.9.3.1.; mitochondria)
and N-acetyl-b-glucosaminidase (E.C. 3.2.1.30.; lysosomes). Results
are expressed as the percentage of enzyme activity, protein or drug
recovered in each fraction. For isopycnic centrifugation, distributions
were standardized for equal density increments ranging from 1.08 to
1.21, as described previously.
13
Biochemical studies
Cell sheets were washed three times in ice-cold 0.9% NaCl, col-
lected by scraping in distilled water and lysed by sonication. Total
phospholipids and cholesterol were extracted and assayed, as
described previously.
7 Proteins were assayed by the Folin–
Ciocalteau/biuret method.
14
Electron microscopy
Sample preparation was performed as described previously.
15,16
Observations were made in a Zeiss electron microscope operated at
80 kV. Morphometric analysis was performed on pictures taken at
random, using the Image J software available from the NIH web site
(http://rsb.info.nih.gov/ij/) and examining a total cell surface of cell
proﬁles of 1000–2000 mm
2. For each cell proﬁle, we manually
selected the zones occupied by electron-dense material (for which a
limiting membrane could not always be clearly recognized) or corre-
sponding to large vesicles ﬁlled with heterogeneous material (see
Figure 3 for examples). Results were expressed as percentage of the
whole cell surface proﬁle, which is numerically identical to the per-
centage of cell volume.
17
Materials
Telavancin hydrochloride (powder for microbiological evaluation
and .90% purity) and [
14C]telavancin triﬂuoroacetate (33.8 mCi/
mmol and radiochemical purity .91%) were supplied by
Theravance, Inc. (South San Francisco, CA, USA). The labelled
drug was mixed with unlabelled telavancin to obtain a speciﬁc
activity of 5 mCi/mmol. Stock solutions were prepared at a ﬁnal con-
centration of 1–2 mg/L by vigorous vortexing in distilled water (the
use of acidiﬁed DMSO recommended by the manufacturer was
avoided because preliminary experiments disclosed a decrease in cell
viability). Oritavancin (supplied as diphosphate salt fully hydrated)
was obtained from Intermune (Brisbane, CA, USA). Vancomycin
was procured as VANCOCIN
w from GlaxoSmithKline, Belgium.
Cell culture or microbiology media were from Invitrogen (Paisley,
Scotland, UK) and Difco (Sparks, MD, USA). Other reagents were
of analytic grade and purchased from E. Merck AG (Darmstadt,
Germany) or Sigma-Aldrich-Fluka (St Louis, MO, USA).
Results
Inﬂuence of telavancin on pericellular membrane integrity
In preliminary experiments, we measured the release of lactate
dehydrogenase, a cytosolic enzyme, from cells exposed to tela-
vancin (90 mg/L, corresponding to the human Cmax
18), in com-
parison with vancomycin (50 mg/L, corresponding to the human
Cmax
19) and oritavancin (25 mg/L, corresponding to the human
Cmax
20). No difference in controls (5.0 + 0.2%) was seen with
telavancin (4.9 + 1.0%) or vancomycin (5.0 + 1.5%) in J774
macrophages after 24 h of incubation, whereas oritavancin
induced a small but signiﬁcant increase in enzyme release
(15.5 + 1.5%; P , 0.001; n ¼ 3 for all conditions). No signiﬁ-
cant effect was seen for ﬁbroblasts after 72 h of incubation
between controls (13.4 + 3.7%) and cells incubated with tela-
vancin (16.9 + 2.5%), vancomycin (17.1 + 1.3%) or oritavan-
cin (18.2 + 3.0%; n ¼ 3 for all testing conditions).
Kinetics of uptake and release of telavancin
Figure 1(a and b) shows the kinetics of uptake of telavancin in
J774 macrophages and ﬁbroblasts incubated with an extracellular
concentration of 90 mg/L. The uptake proceeded linearly over
time at a rate that was similar in both cell types (see ﬁgure cap-
tions for details). Figure 1(c and d) examines the uptake of
Telavancin and eukaryotic cells
1289telavancin at increasing extracellular concentrations and at ﬁxed
time points (24 h for macrophages and 72 h for ﬁbroblasts). The
uptake was linearly related to the extracellular concentration in
both cell types, allowing us to calculate a clearance rate for all
conditions shown in Figure 1 of ~10 mL/mg of cell protein
per h. For macrophages, we also examined the drug efﬂux (after
an initial uptake of 12 h in the presence of 90 mg/L telavancin),
which occurred at an apparent rate  5.7-fold lower than that of
inﬂux (Figure 1a).
The inﬂuence of serum on telavancin uptake was examined
in J774 macrophages by performing experiments in culture
medium not supplemented with calf serum. The incubation was
limited to 5 h to ensure maintenance of cell viability. Telavancin
uptake remained linear over the 10–90 mg/L range of extracellu-
lar concentrations, but proceeded at a rate ~1.7-fold faster than
in the presence of serum (data not shown).
Subcellular distribution of telavancin
The subcellular distribution of cell-associated telavancin was
examined in homogenates obtained from J774 macrophages
incubated for 24 h with the drug at an extracellular concentration
of 90 mg/L. The distribution of cell-associated telavancin and
N-acetyl-b-glucosaminidase (lysosome marker) among the
unbroken cells/nuclei, granules/membranes and supernatant frac-
tions was similar (35% and 27%, 55% and 67% and 10% and
6%, respectively). The granule/membrane fraction was therefore
subfractionated by isopycnic centrifugation. The density distri-
bution of telavancin, in comparison with that of
N-acetyl-b-glucosaminidase (lysosomes), cytochrome c oxidase
(mitochondria) and inosine 50-diphosphatase (plasma/endoplas-
mic reticulum membranes), is shown in Figure 2. The distri-
bution pattern of telavancin was largely superimposable on that
of the N-acetyl-b-glucosaminidase, clearly dissociated from that
of cytochrome c oxidase and also distinct from that of inosine
50-diphosphatase.
Ultrastructural alterations
Electron microscopy was used to examine whether telavancin
induces morphological alterations in the subcellular organelles of
cells incubated in its presence. Figure 3 shows selected pictures of
Figure 1. (a and b) Kinetics of uptake of telavancin (ﬁlled symbols and continuous line) in J774 macrophages (a) or embryo ﬁbroblasts (b) incubated for the
indicated times with an extracellular concentration of 90 mg/L at 378C in medium supplemented with 10% fetal calf serum. (a) Kinetics of efﬂux of the drug
from J774 macrophages exposed to telavancin (90 mg/L) for 12 h and re-incubated in a drug-free medium for an additional 24 h (open symbols and broken
line) are also shown. (c and d) Cellular concentration of telavancin in J774 macrophages (c) or embryo ﬁbroblasts (d) incubated at 378C for 24 h or 72 h,
respectively, in the presence of telavancin at the extracellular concentrations indicated on the abscissa. Results are given as arithmetic means + SD (n ¼ 3)
and analysed by linear regression to calculate the corresponding clearances (mL/mg of protein/h): J774 macrophages, 9.6 + 0.6 (R
2 ¼ 0.98; a) and
10.0 + 0.4 (R
2 ¼ 0.99; c); ﬁbroblasts, 8.2 + 0.4 (R
2 ¼ 0.97; b) and 9.0 + 0.7 (R
2 ¼ 0.98; d).
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blasts (90 mg/L; 24 and 72 h, respectively). There was an enlarge-
ment of lysosomes that were ﬁlled with a pleiotropic material,
made of partly highly osmiophilic, concentric structures and partly
of a more loose appearance material.
To gain quantitative information on these changes, a mor-
phometric analysis was performed on pictures taken at random.
Figure 4 shows the relative abundance of these abnormal lyso-
somal proﬁles in cells incubated with three different concen-
trations of telavancin, in comparison with control cells or cells
exposed to 50 mg/L vancomycin or 20 mg/L oritavancin. In
macrophages (24 h incubation) as well as in ﬁbroblasts (72 h
incubation), telavancin induced a concentration-dependent
increase in the percentage of cell volume occupied by over-
loaded lysosomes. The morphometric analysis showed that: (i)
changes induced in ﬁbroblasts were more marked than those in
macrophages (which may have been a consequence of the
longer incubation time in ﬁbroblasts); (ii) incubation of macro-
phages with 25 mg/L telavancin or of ﬁbroblasts with 90 mg/L
caused changes similar to those seen with 50 mg/L vancomy-
cin in either cell types and (iii) alterations induced by telavan-
cin at the highest concentration tested (90 mg/L) were
considerably milder than in cells incubated with 20 mg/L orita-
vancin in both cell types.
Inﬂuence of telavancin on cell phospholipid and
cholesterol contents
In view of the ultrastructural changes observed, we looked for
changes in phospholipids and cholesterol content of cells
exposed to 90 mg/L telavancin in comparison with vancomy-
cin (50 mg/L) and oritavancin (25 mg/L). Figure 5 illustrates
the data obtained after 24 h in macrophages and 72 h in ﬁbro-
blasts. Neither telavancin nor vancomycin caused detectable
increase in the phospholipid content. In contrast, oritavancin
induced signiﬁcant increases in the phospholipid content in
both cell types. Telavancin and vancomycin caused a slight
but not signiﬁcant increase in the cholesterol content, whereas
oritavancin again induced a marked, statistically signiﬁcant
increase.
Figure 2. Density distribution of marker enzymes [N-acetyl-b-
glucosaminidase (lysosomes), cytochrome c oxidase (mitochondria) and
inosine 50-diphosphatase (plasma and endoplasmic reticulum membranes)]
and of telavancin after isopycnic centrifugation in a linear sucrose gradient
of a granule fraction prepared from homogenates of J774 cells that were
incubated for 24 h with 90 mg/L telavancin at 378C in medium
supplemented with 10% fetal calf serum. The ordinate shows the percentage
of each constituent recovered in each fraction.
Figure 3. Selected pictures illustrating typical changes observed in macrophages (a) and ﬁbroblasts (b) after incubation with 90 mg/L telavancin for 24 or
72 h, respectively. Both cells show markedly enlarged and ill-shaped lysosome-like bodies with a pleiotropic material that is highly osmiophilic (often
organized in a distorted concentric fashion). (c) Example of loose material and (d) example of highly osmiophilic material organized in multiple separate
bodies. Bars are 1 mm. The dotted lines show examples of proﬁles selected for morphometric analysis: i, a large proﬁle showing mainly a moderately
osmiophilic and pleiomorphic material; ii, a small proﬁle showing mainly osmiophilic material [possibly a polar section of a lysosome with mixed content
(as in iii), but cut as shown by the arrow].
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incubation, respectively, in control conditions or in the presence of 5, 25 or 90 mg/L telavancin (TLV), 50 mg/L vancomycin (VAN) or 20 mg/L oritavancin
(ORI). Results are expressed as percentage of the cell surface occupied by the electron-dense material and/or large vesicles ﬁlled with a material of
undetermined nature. Surface analysed was ~2000 mm
2 for macrophages and 1000 mm
2 for ﬁbroblasts.
Figure 5. Total phospholipid content (upper panels) or total cholesterol content (lower panels) of J774 mouse macrophages (left-hand panels) or rat embryo
ﬁbroblasts (right-hand panels) exposed for 24 and 72 h, respectively, to glycopeptides at their human Cmax (VAN, vancomycin 50 mg/L; TLV, telavancin
90 mg/L and ORI, oritavancin 25 mg/L). Results are expressed as percentages of control values for total phospholipids and cholesterol. Values are arithmetic
means + SD (n ¼ 6–8). Values for control macrophages and ﬁbroblasts were, respectively, 204 + 10 and 295 + 8 nmol/mg of protein for total
phospholipids and 72 + 3 and 130 + 16 nmol/mg of protein for total cholesterol. Statistical analysis (ANOVA): ***P , 0.001, **P , 0.01, *P , 0.05
when compared with the matching control. Other differences were not signiﬁcant.
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The present study provides evidence that telavancin is taken up
by cultured macrophages where it becomes associated with lyso-
somes, as assessed by cell fractionation studies. These results
rationalize our previous data, showing that telavancin exerts a
marked antibiotic activity against intraphagocytic S. aureus,
which is known to develop in the phagolysosomes of infected
macrophages.
21,22
The accumulation level reached by telavancin in macro-
phages at 24 h ( 45-fold) is intermediate between that recorded
previously in the same conditions for vancomycin ( 8-fold) and
oritavancin ( 370-fold).
12 Its uptake is not speciﬁc to phagocy-
tic cells, as it is also observed with ﬁbroblasts, both cell types
taking up the drug at similar rates. The entry of drugs into lyso-
somes may occur through either diffusion/segregation or pinocy-
tosis,
23 as illustrated by the behaviour of macrolides
8 and
aminoglycosides,
24 respectively. Diffusion–segregation seems
unlikely in view of the slow efﬂux of telavancin, as this process
is usually considered to be reversible (although binding of the
drug to intracellular constituents could explain this slow efﬂux,
as is observed for azithromycin in ﬁbroblasts
16). Pinocytosis,
therefore, appears more plausible, especially if considering the
size of the molecule that would prevent its fast diffusion through
membranes. However, the clearance rates recorded here
( 10 mL/mg of protein/h) are ~15- to 30-fold higher than those
reported for ﬂuid-phase pinocytosis markers ( 0.7 mL/mg of
protein/h in macrophages
15 and  0.3 mL/mg of protein/h in
ﬁbroblasts
24). Telavancin uptake, therefore, should involve a
process of adsorptive pinocytosis (through binding to cell
surface; see discussion and modelling in Silverstein et al.
25)
However, the lack of saturation of telavancin uptake upon
increase of its extracellular concentration is intriguing as this (i)
is an hallmark of adsorptive pinocytosis
25 and (ii) was observed
for oritavancin.
12 The initial uptake clearance rate of oritavancin,
however, is considerably larger ( 150 mL/mg of protein/h),
12
which indicates that binding of telavancin should be much
weaker and may not actually show saturation in the concen-
tration range investigated here. A weaker membrane binding of
telavancin is actually consistent with its lower lipophilicity
when compared with oritavancin (reported logP values of 0.6
for telavancin versus 4.1 for oritavancin) [Advanced Chemistry
Development Software Solaris V4.67, Sci Finder Scholar 2006,
American Chemical Society, Washington, DC, USA].
Beyond its therapeutic interest, the lysosomal accumulation
of telavancin may also be responsible for the morphological
alterations observed in cells exposed to the drug. Yet, these
changes appear quantitatively minor, as is also the case for van-
comycin. Moreover, and in contrast to what is observed with ori-
tavancin,
7 telavancin did not signiﬁcantly affect phospholipid or
cholesterol cellular levels. This difference may be related to the
lower uptake of telavancin, although we cannot exclude, at this
stage, a true difference in the intrinsic capacity of the two mol-
ecules to interfere with lipid metabolism. Further studies are
required to determine the exact nature of the accumulated
material and to decipher the underlying molecular mechanisms.
These may be more complex than those evidenced for aminogly-
coside antibiotics, which mainly induce an accumulation of
phospholipids.
26 Interestingly, telavancin was without detectable
effect on lactate dehydrogenase release. This suggests that the
membrane-destabilizing properties exerted by telavancin towards
bacterial membranes,
3 which probably contribute to its marked
bactericidal effect, involve constituents that are speciﬁc to or
more abundant in prokaryotic cells.
Independent studies have shown that telavancin accumulates
in human alveolar macrophages, reaching a cellular concen-
tration of ~50 mg/L within 8–24 h after systemic administration
of therapeutic doses.
5,27 In our experiments, macrophages
exposed for 24 h at 90 mg/L have an apparent cellular concen-
tration of 4 mg/mL [based on an estimated mean cellular
volume of 5 mL/mg of protein (see Van Bambeke et al.
12 and
references cited therein)]. The lower cellular uptake of telavan-
cin reported in vivo may result from (i) its high protein binding
( 90% to 93%) and (ii) the ﬂuctuation of its serum levels
related to its once-daily administration and its half-life of
7.5 h.
18 As extensively discussed in previous publications,
6,7,12,22
our cellular model suffers from the limitation that it does not
take into account these two important pharmacokinetic determi-
nants. This may lead to an overestimation of the accumulation
of telavancin versus that of vancomycin, for which the free frac-
tion in vivo oscillates between 10% and 55%.
19 Thus, assuming
that only the free fraction of telavancin is available for the
uptake by macrophages in vivo, its effective extracellular con-
centration will oscillate between  10 and 0.5 mg/L, which, in
our model, would create a cellular concentration of  0.24 mg/
mg of protein (i.e.  48 mg/L). At this concentration, which is
of the same order of magnitude as that observed in vivo, telavan-
cin does not cause any morphological change in our model.
Taken together, our data further document the tissue-
directed pharmacokinetics of lipoglycopeptides.
28 As telavancin
is clearly superior to vancomycin with respect to bactericidal
activity towards both extracellular and intraphagolysosomal
S. aureus
6 while showing a similar cellular safety proﬁle
(as far as lipid metabolism and subcellular morphology are
concerned), the data support its potential interest for the treat-
ment of infections where intracellular foci are present.
29
Further studies using in vivo models are, however, required to
conﬁrm the improved intracellular efﬁcacy and cellular inocu-
ity of telavancin.
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